1141 related articles for article (PubMed ID: 17680909)
1. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma.
Ozdemir C; Yazi D; Gocmen I; Yesil O; Aydogan M; Semic-Jusufagic A; Bahceciler NN; Barlan IB
Pediatr Allergy Immunol; 2007 Sep; 18(6):508-15. PubMed ID: 17680909
[TBL] [Abstract][Full Text] [Related]
2. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.
Eifan AO; Akkoc T; Yildiz A; Keles S; Ozdemir C; Bahceciler NN; Barlan IB
Clin Exp Allergy; 2010 Jun; 40(6):922-32. PubMed ID: 20100188
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan.
Niu CK; Chen WY; Huang JL; Lue KH; Wang JY
Respir Med; 2006 Aug; 100(8):1374-83. PubMed ID: 16403616
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial.
Karakoc-Aydiner E; Eifan AO; Baris S; Gunay E; Akturk E; Akkoc T; Bahceciler NN; Barlan IB
J Investig Allergol Clin Immunol; 2015; 25(5):334-42. PubMed ID: 26727762
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of sublingual immunotherapy in children with dust mite allergic asthma].
Ma XP; Muzhapaer D
Zhongguo Dang Dai Er Ke Za Zhi; 2010 May; 12(5):344-7. PubMed ID: 20497640
[TBL] [Abstract][Full Text] [Related]
7. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study.
Lue KH; Lin YH; Sun HL; Lu KH; Hsieh JC; Chou MC
Pediatr Allergy Immunol; 2006 Sep; 17(6):408-15. PubMed ID: 16925685
[TBL] [Abstract][Full Text] [Related]
9. Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy.
Marcucci F; Sensi L; Di Cara G; Salvatori S; Bernini M; Pecora S; Burastero SE
Pediatr Allergy Immunol; 2005 Sep; 16(6):519-26. PubMed ID: 16176400
[TBL] [Abstract][Full Text] [Related]
10. [Preventive immunotherapy].
Boquete M; Carballada F; Expósito F; González A
Allergol Immunopathol (Madr); 2000; 28(3):89-93. PubMed ID: 10867376
[TBL] [Abstract][Full Text] [Related]
11. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites.
Bahceciler NN; Arikan C; Taylor A; Akdis M; Blaser K; Barlan IB; Akdis CA
Int Arch Allergy Immunol; 2005 Mar; 136(3):287-94. PubMed ID: 15722639
[TBL] [Abstract][Full Text] [Related]
12. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes.
Keles S; Karakoc-Aydiner E; Ozen A; Izgi AG; Tevetoglu A; Akkoc T; Bahceciler NN; Barlan I
J Allergy Clin Immunol; 2011 Oct; 128(4):808-815.e7. PubMed ID: 21641635
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F
JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376
[TBL] [Abstract][Full Text] [Related]
14. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial.
Mosbech H; Deckelmann R; de Blay F; Pastorello EA; Trebas-Pietras E; Andres LP; Malcus I; Ljørring C; Canonica GW
J Allergy Clin Immunol; 2014 Sep; 134(3):568-575.e7. PubMed ID: 24797423
[TBL] [Abstract][Full Text] [Related]
15. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study.
Yukselen A; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB
Int Arch Allergy Immunol; 2012; 157(3):288-98. PubMed ID: 22041501
[TBL] [Abstract][Full Text] [Related]
16. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite.
Maestrelli P; Zanolla L; Pozzan M; Fabbri LM;
J Allergy Clin Immunol; 2004 Apr; 113(4):643-9. PubMed ID: 15100667
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of sublingual specific immunotherapy in intermittent and persistent allergic rhinitis in children: an observational case-control study on 171 patients. The EFESO-children multicenter trial.
Acquistapace F; Agostinis F; Castella V; Kantar A; Novembre E; Perrone MR; Pietrasanta M; Sambugaro R; Milani M
Pediatr Allergy Immunol; 2009 Nov; 20(7):660-4. PubMed ID: 19320852
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the antiinflammatory and clinical effects of sublingual immunotherapy with carbamylated allergoid in allergic asthma with or without rhinitis. A 12-month perspective randomized, controlled, trial.
La Grutta S; Arena A; D'Anneo WR; Gammeri E; Leonardi S; Trimarchi A; Platania D; La Rosa M
Eur Ann Allergy Clin Immunol; 2007 Feb; 39(2):40-4. PubMed ID: 17441414
[TBL] [Abstract][Full Text] [Related]
19. Sublingual immunotherapy not effective in house dust mite-allergic children in primary care.
de Bot CM; Moed H; Berger MY; Röder E; Hop WC; de Groot H; de Jongste JC; van Wijk RG; Bindels PJ; van der Wouden JC
Pediatr Allergy Immunol; 2012 Mar; 23(2):150-8. PubMed ID: 22017365
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Sublingual Immunotherapy in the Treatment of HDM-Induced Nasobronchial Allergies: A 3-Year Randomized Case-Control Study From Kashmir.
Baba SM; Rasool R; Gull A; Qureshi TA; Beigh AH; Qadri Q; Shah ZA
Front Immunol; 2021; 12():723814. PubMed ID: 34721385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
